Clinical trial · Observational
Evaluate the Prognostic Significance of Changes in the Systemic Immune-Inflammation Index in Patients with AGC Treated with ICI Therapy.
Systemic Immune-Inflammation Index As a Predictor of Neoadjuvant Treatment Efficacy in Advanced Gastric Cancer Based on a Dynamic Clinical Model
NCT06706466CI-TRIAL-00083029completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The SIIR during neoadjuvant therapy can serve as a specific biomarker for predicting the efficacy of immunotherapy in patients with advanced gastric cancer.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastric Cancers | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
| Immunotherapy Gastrict Cancer | Gastric Neoplasm | PROBABILISTIC | 0.70 |
| Inflammation Biomarkers | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| observational study | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- SIIR-Dec
- description
- Patients with an SIIR of ≥-0.3 after ICI treatment
- interventionNames
- Other: observational study
- label
- SIIR-non-Dec
- description
- Patients with an SIIR of \< -0.3 after ICI treatment
- interventionNames
- Other: observational study
Primary outcomes (1)
- measure
- survival
- timeFrame
- 36 months
- description
- Telephone follow-up
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: (1) preoperative clinical staging of cT2-4NxM0; (2) primary gastric adenocarcinoma confirmed via pathology; (3) no distant metastasis to the liver, lungs, or abdominal cavity as confirmed through preoperative chest X-ray or chest CT, abdominal ultrasound, and abdominal CT; (4) All patients received neoadjuvant therapy, followed by gastrectomy. Exclusion Criteria: We excluded patients under 18 or over 80, those with distant metastasis, remnant gastric cancer, prior radiotherapy, other malignancies, abdominal surgery history (except laparoscopic cholecystectomy), recent unstable angina, myocardial infarction, cerebrovascular accidents, or those requiring emergency surgery due to disease progression
References
Publications (0)
Data not yet available
No reference posted for this study.